FDA issues warning letters to compounded GLP-1 marketers

Several telehealth companies were cited over labelling and marketing claims, not over patient harm.

Regulatory2026-02-20
Direct answer

Several telehealth companies were cited over labelling and marketing claims, not over patient harm.

All-in monthly cost at 10 mg

NexLife$215Join Fridays$249Yucca Health$258Mochi Health$278IVIM Health$278ShedRx$289SkinnyRx$299Amble Health$300TrimRx$349Lavender Sky Health$352Found$398MEDVi$399
Medication plus any recurring membership fee, at 10 mg. Lower is better. Captured 2026-08-05.

Letters dated 20 February 2026 cite misbranding: marketing that blurred the line between a compounded preparation and an FDA-approved product, and in at least one case implying the telehealth company was itself the compounding pharmacy.

A warning letter is not a finding of patient harm and not a ban. It is a public record you can search by company name before enrolling anywhere.

The practical lesson is narrow: read what a programme claims about FDA status.

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.

Primary sources

Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.

  1. FDA — Human Drug Compounding
  2. FDA — Warning Letters
  3. FDA — Drug Shortages
  4. FTC — Health Products Compliance Guidance
  5. FDA — Counterfeit medicine

Next step

Compare every programme on one screen

The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.

Open the comparison matrix How all-in cost is calculated